Gene therapy trial is derailed after getting hit by the latest serious adverse event in the field — shares crash
You can rack up another serious safety concern flagged by a gene therapy developer.
Today it’s Adverum, which is reporting that a patient who received a high dose of their gene therapy for diabetic macular edema experienced a loss of vision in a treated eye. The patient was given a high dose (6 x 10^11 vg/eye) of ADVM-022, with a case of hypotony developing, characterized by a decrease in ocular pressure.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.